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STRUCTURED ABSTRACT (250 words): 
 
"Background/aims" 
 
Cataract is an important source of visual loss in patients with uveitis. Whether or not 
outcomes of cataract surgery in eyes with uveitis are worse compared to non-uveitic 
eyes have to date been compromised by lack of reliable estimates of benefit and 
harm, which require data from large cohorts. 
 
"Methods" 
 
Electronic medical record data were extracted from eight independent UK clinical 
sites for eyes undergoing cataract extraction between January 2010 and December 
2014. 1173 eyes with a recorded diagnosis of uveitis were compared to a reference 
group of 95573 eyes from the same dataset. 
 
"Results" 
 
Uveitic eyes represented 1.2% of all eyes undergoing cataract surgery. Eyes in the 
uveitic group had worse pre-operative visual acuity (0.87 vs 0.65 logMAR units), 
were from younger patients and had shorter axial lengths and a higher incidence of 
ocular co-pathology including glaucoma. A greater number had documented small 
pupils, required additional surgical procedures, developed more intraoperative 
complications and had poorer post-operative visual acuity at all timepoints measured 
up to 6 months (0.41 vs 0.27 logMAR units at 12-24 weeks). 
 
"Conclusion" 
 
This large study cohort of eyes with a diagnosis of uveitis undergoing cataract 
surgery highlights more precisely the complex surgical demands, co-pathology and 
worse visual outcomes in this group. This data will allow more accurate pre-operative 
counselling and planning. Although improvement in visual acuity is achieved in most 
cases, prognosis should be guarded so patient expectations are met. Compared to 
the non-uveitic population, the mean post-operative visual acuity is between one to 
two lines worse at all time-points.   
INTRODUCTION: 
 
Cataract is a major cause of visual loss in patients with uveitis; up to 40% of the 
visual loss is either solely or largely due to cataract [1]. Surgical treatment may be 
effective but is associated with higher complication rates than in eyes without 
previous uveitis. Quantifying this risk is important in order to inform patients and 
surgeons as to the likely short- and long-term benefit or harm of undertaking cataract 
surgery, and may affect the timing of such surgery.  
 
Currently most data on cataract surgery in patients with uveitis comes from small 
case series or cohort studies, with data gathered over long time periods to attain 
sufficient numbers. As this may be so long that practice changes, the studies may 
not reflect current practice or be generalisable [2-7]. The outcome of cataract surgery 
in patients with uveitis is regarded as far less predictable than in most groups of 
patients, due to numerous factors including technical challenges at the time of 
surgery, the uncertain impact of inflammatory sequelae and the variable and 
unpredictable reversibility of these complications.  
 
The relative paucity of evidence on which to base treatment decisions was noted in a 
survey of uveitis practioners by Sreekantham et al, in which the majority stated that 
there was no or only low level published evidence to support key treatment decisions 
regarding perioperative management and choice of intraocular lens in these patients 
[8]. There is a real need for large volume population data in uveitic patients to help 
bridge this evidence gap, improving the decision-making process and helping inform 
patient and clinician expectations around outcome.  
 
The use of electronic medical record (EMR) systems provides a way of acquiring 
large-scale pre-specified standardised data that are relevant to daily practice. In the 
context of cataract surgery we have recently reported on a multicenter database 
study of 81 984 eyes undergoing cataract surgery in the United Kingdom [9]. The 
United Kingdom National Health Service is an ideal setting for this study because it 
serves more than 90% of the population for cataract surgery and there has been 
widespread adoption of EMR systems that mandate collection of detailed 
standardised datasets developed by The Royal College of Ophthalmologists [10,11]. 
The ability to pool anonymised data from multiple centres enables relatively precise 
estimates of complication rates even for uncommon conditions such as uveitis. It also 
means that there is sufficient power for hypothesis testing. This is particularly 
relevant to complex diseases such as uveitis, for which multiple complications of the 
disease present at the time of surgery may affect visual outcome and would ideally 
be factored into any estimate of the risk of undertaking surgery.  
 
The primary aim of this study is to define estimates of the likelihood and magnitude 
of visual gain and the risk of intra-operative and post-operative complications in 
uveitic eyes undergoing cataract surgery in a real-world setting compared to eyes 
without uveitis.  
 
  
MATERIALS & METHODS  
 
Eight independent NHS hospital ophthalmology departments in the United Kingdom 
using the same EMR system (Medisoft Ophthalmology, Medisoft Limited, Leeds, UK) 
provided routinely captured clinical data, based upon nationally standardised 
datasets approved by The Royal College of Ophthalmologists [10]. Lead clinician and 
Caldicott Guardian approval was obtained for all sites before extraction of the 
anonymised data. The Declaration of Helsinki, UK Data Protection Act and NIHR 
guidance on ethical approval were adhered to.   
 
The study period was from 1st January 2010 to the 31st December 2014. All sites 
performed small-incision day-case phacoemulsification surgery. Raw data were 
electronically extracted and anonymised in May 2015. No verification against paper 
records was made as part of this study, so fidelity of documentation cannot be 
determined. 
 
Following the decision to operate by an ophthalmologist, all sites recorded 
standardised nurse-led pre-operative assessment (with multiple standard data fields 
mandated by the EMR) and biometry. Routine post-operative care included a single 
visit 4-6 weeks following surgery conducted by a specialist nurse or optometrist. 
Eyes identified as high risk, such as those with known uveitis, were more likely to be 
reviewed earlier by an ophthalmologist. 
 
Data fields extracted on demographics and pre-operative characteristics included: 
age, gender, laterality, visual acuity, intra-ocular pressure, diabetic status and 
ETDRS grading if relevant, use of preoperative intravitreal steroid, use of pre-
operative topical NSAIDs and the presence of glaucoma, trabeculectomy and other 
pre-existing co-pathologies and use of prostaglandin analogues.  
 
Data fields extracted from intra-operative records included: pupil size, grade of 
operating surgeon, use of pupil manipulation, any intraoperative complications, 
capsular rupture with or without vitreous loss and combined procedures such as pars 
plana vitrectomy. 
 
Data fields extracted from post-operative visits included: visual acuity, intra-ocular 
pressure, use of intravitreal corticosteroid or topical NSAIDs, and whether there was 
any record of the development of cystoid macular oedema. 
  
All eyes of patients who did not have their diabetic status recorded were excluded 
from subsequent analyses.  The remaining eyes were classified as either uveitic or 
non-uveitic.  Eyes were classified as uveitic if the term ‘uveitis’ was selected in the 
mandatory co-pathology field for the operated eye at the time of surgery or if there 
was any recorded diagnosis including the word ‘uveitis’ or either of the two terms 
‘neuroretinitis’ or ‘ocular sarcoidosis’ at any preoperative visits. The latter terms were 
included as pre-existing specific diagnoses available from the limited pre-populated 
diagnosis database not featuring the term ‘uveitis’. In the EMR version used more 
common specific diagnoses were not readily available. 
 
Pre-operative visual acuity and IOP used the values recorded closest to the date of 
surgery. If no value was recorded within 3 months prior to surgery the eye was 
excluded from analysis.  Post–operative visual acuity and IOP used the last recorded 
measurements within each time period.  If visual acuity was recorded in Snellen 
fractions these were converted to logMAR units with values corresponding to count 
fingers (CF), hand movements (HM), perception of light (PL) and no PL (NPL) 
substituted with 2.10, 2.40, 2.70 and 3.00 logMAR units respectively.[10] 
 
Pre-existing co-pathologies were not mutually exclusive and were analysed 
individually but the aggregate number of co-pathologies for each eye (single or 
multiple) were also presented.   
 
Due to the anonymised extraction of records, it was not possible in this study to 
identify, which patient each eye belonged to and therefore it was not possible to 
differentiate between two eyes from the same individual. Therefore all eyes were 
treated as independent units for the purpose of data analysis.   
 
Comparisons of multiple pre, intra and post-operative characteristics and outcomes 
were made between eyes with uveitis (uveitic group) and those with no uveitis 
(reference group). To prevent the confounding effect of diabetic macular oedema on 
the occurrence of pseudophakic macular oedema, eyes of patients with diabetes 
were excluded from this particular analysis. Differences between groups were tested 
for statistical significance using multiple t test analysis with the Holm-Šídák method 
for multiple comparisons or chi-square tests for independence as indicated in figure 
legends using GraphPad Prism version 6.00 (GraphPad Software, La Jolla California 
USA). Linear regression was performed using STATA (StataCorp. 2013. Stata 
Statistical Software: Release 13. College Station, TX: StataCorp LP). 
RESULTS 
 
An initial dataset was collected on a total of 111 641 eyes comprising all eyes 
undergoing cataract surgery between January 2010 and December 2014 at 8 
centres.  Of this cohort, 14 895 eyes were excluded as the diabetic status was not 
recorded.  Of the remaining eyes, 1173 eyes were classified into the uveitis group 
and 95 573 eyes were classified into the non-uveitis reference group.  
 
Tables 1 and 2 show the pre-operative demographic and clinical characteristics of 
the eyes and patients. The uveitic group was associated with a younger age, worse 
visual acuity, and a higher prevalence of co-existing glaucoma, previous 
trabeculectomy, prior use of topical prostaglandin analogues, intravitreal 
corticosteroid administration, and possessing one or more co-existing pathologies, 
shorter axial length and less high myopia. The reference cohort was associated with 
a greater prevalence of type II diabetes and age-related macular degeneration.  
There was no statistically significant difference between the two groups in terms of 
gender, laterality, pre-operative topical NSAID use, the presence of epiretinal 
membrane, amblyopia, corneal pathology, white cataract, previous retinal 
detachment, retinal vein occlusion, optic nerve disease, Pseudoexfoliation or the 
presence of type I diabetes or maculopathy and retinopathy. 
 
Tables 3 and 4 show the differences in intra-operative and post-operative 
characteristics between the two groups. The uveitic group was associated with 
smaller pupil size, having surgery performed by consultant surgeons, requiring 
surgical pupil manipulation, or combined surgery such as planned pars plana 
vitrectomy. A higher incidence of PC rupture was documented when only cases 
performed by senior surgeons were compared between the two groups. No 
correlation between VA gain and total surgeon or cataract numbers at different sites 
was seen (Supplementary Figure 1). 
 
The uveitic group was associated with poorer visual acuity at all three post-operative 
time points of 4 weeks, 4-12 weeks and 12-24 weeks, higher post-operative IOP and 
over twice as high preponderance of post-operative macular oedema (3.33% vs 
1.35% p<0.0001) once eyes of diabetic patients were excluded from the analysis. 
Eyes of patients with uveitis had a mean pre-op VA of 0.87 compared to 0.65 
LogMAR units in controls. At 12-24 weeks post-operatively, mean VA was 0.41 and 
0.27 LogMAR units respectively. As a cohort, on average both groups of eyes 
improved by 3 to 4 lines on the LogMAR chart. Using a multivariate regression model 
controlling for pre-operative VA, the mean post-operative VA was significantly 
associated with uveitic status (coefficient 0.085; 95% confidence interval [CI]: 0.05-
0.12; t = 4.86; p < 0.01). When controlling for pre-operative VA, the regression 
equation is as follows: Mean post-operative VA = 0.095 + 0.085 x uveitic status (1 or 
0) + 0.28 x pre-operative VA. This implies both improve proportionately to pre-
operative VA, although eyes with uveitis were on average 0.085 LogMAR worse 
post-operatively compared to controls. 
 
Marked visual harm defined as a loss greater than 0.3 logMAR units from pre-
operative baseline was assessed at 12-24 weeks post-op where data was available. 
The incidence was 3.8% of eyes in the uveitic group (16 of 421 eyes) however this 
was not statistically different from those in the control group at 2.9% (826 of 28305, 
p=0.3577, Chi-square). Eyes with uveitis suffering marked visual harm showed no 
consistent intraoperative complications, but had a higher mean IOP (21.3 vs 
15.9mmHg) and greater incidence of glaucoma surgery (12.5% vs 1.2%).  
  
DISCUSSION 
 
This is the largest real-world study of cataract surgery in patients with uveitis 
reported and provides clear evidence of the burden of disease, additional risk of 
complications and worse visual outcomes in this cohort. Based on the analysed 
96746 eyes from eight different centres, eyes with uveitis are noted to account for 
1.2% of all cases and represent a younger, surgically demanding cohort, which may 
require significant additional resources at each treatment stage. Our study shows 
that whilst surgery for cataract in eyes with uveitis is associated with an improvement 
in mean VA, there are significantly higher rates of both intra-operative and post-
operative complications with final VA in the uveitic cohort worse than the non-uveitic 
cohort at all time-points.  
 
Visual Outcome 
 
The key finding that cataract surgery is associated with improved visual outcome in 
patients with uveitis is consistent with previous studies. A systematic review analysed 
13 studies of phacoemulsification, 10 of extra-capsular cataract extraction and eight 
of pars plana lensectomy in mixed groups of uveitis patients. It noted overall 71% 
that had intraocular lens (IOL) implantation achieved 20/40 postoperatively vs 52% of 
those left aphakic [12]. The review however contains a high proportion of older 
studies (up to 1997 for phacoemulsification) and mixes prospective and retrospective 
designs. Our study showed that of 1173 uveitic eyes undergoing cataract surgery 
between 2010 and 2014, 69% achieved a visual acuity of at least 20/40 in the 4-12 
week post-op interval. Given recent advances in surgical (IOL, phacoemulsification 
machine, surgical technique) and medical aspects (increased range of drugs to 
control uveitis including local therapies) it is salutary that visual outcomes observed 
are similar to the systematic review, suggesting that there has not been a significant 
improvement in outcome during the intervening period.  
 
More recent studies are limited by their size (and in some cases design) but do 
provide a useful comparison, with similar outcomes to our study. A single-surgeon 
retrospective study in 171 uveitic eyes reported that at 6 months a VA of 20/40 or 
better was achieved in 71% of eyes [6]. A small non-masked RCT investigating the 
effect of perioperative oral corticosteroid in 52 uveitic eyes undergoing 
phacoemulsification reported a VA improvement from 0.68 to 0.31 logMAR in the 
standard therapy group (intensive topical corticosteroid) and from 0.75 to 0.20 in the 
intervention group (intensive topical plus oral corticosteroid) [13]. During the two-year 
follow-up of the Multicenter Uveitis Steroid Treatment Trial, 117 eyes underwent 
cataract surgery where 62% of eyes achieved a VA of 6/12 or better at the 3 month 
post-operative visit, from a median of 56 letters at baseline to 79 letters at 3 months 
[14]. A multicentre trial randomising 126 uveitic eyes to phacoemulsification vs small 
incision cataract surgery noted that 44% achieved at least 20/36 and 91% achieved 
at least 20/63 at 6 months in the phacoemulsification group [15]. 
 
Our study provides a large survey of contemporary practice in an unselected uveitis 
cohort where all data was gathered into prospectively fixed data fields, then analysed 
retrospectively. This has clear advantages over smaller retrospective studies in terms 
of scale, but also avoids the selection bias inherent in studies that arise from single 
tertiary centres. The eight centres included in our study comprise a wide range of 
settings and size, providing a good representation of the UK population. 
 
 
 
 
Risk of surgery 
 
This study confirms that the uveitic population differs in being younger, with more 
advanced cataract and having much higher rates of co-pathology. Many of these 
pathologies will limit visual outcome. Surgery is shown to be technically more 
challenging with small pupils recorded in nearly a third of all uveitic eyes and 
significantly higher rates of additional procedures being required. The additional skill 
required is demonstrated by the larger proportion performed by Consultant (senior) 
surgeons. 
 
It is likely the worse pre-operative VA represents a combination of the presence of 
more advanced cataract in this cohort combined with higher rates of visually 
significant pre-operative co-pathology, which is supported by the fact that mean VA 
fails to recover to the same levels as in the non-uveitic cohort. Whilst over two-thirds 
of eyes operated upon gained VA of at least 20/40, the more guarded prognosis 
might mean surgeon and patient preference may delay the decision to operate or be 
enforced by difficulties in achieving inflammatory control. Our linear regression model 
indicates despite uveitic status, pre-operative VA is the key determinant of post-
operative VA. This association suggests delaying until VA significantly deteriorates 
might not always be the preferred option. 
 
Direct comparison with other studies is difficult due to the variation in reporting. 
However, where evidence is available, studies report a high rate of additional 
procedures, notably intraoperative iris hook use between 19 and 67%, but a low risk 
of intraoperative complications [6,13,15]. The largest of these studies reported no 
posterior capsular ruptures in any of 171 uveitic eyes undergoing surgery [6].  
 
Limitations 
 
This study has a number of limitations. First, it is entirely observational. It allows the 
detection of interesting associations, estimates of risk and provides valuable 
benchmark data, but cannot provide high-level evidence to justify any particular 
intervention that a clinical trial might. Furthermore, EMR data could not be readily 
checked against paper medical notes, so the exact degree of verification is uncertain. 
 
Second, a number of datafields are non-compulsory leading to higher rates of 
missing data than would be seen in a prospective clinical trial. Additionally, the 
accuracy of data entry is not subject to the routine audits of a trial. Our study does 
benefit from almost complete datasets for key variables of VA and presence of 
complications, which are compulsory fields mandated by the software. In contrast 
some other variables, which might be used to stratify patient risk are not compulsory, 
and thus are not available for analysis in our dataset. For example, details of the 
uveitic syndrome are not compulsory and so we have not attempted subgroup 
analysis by uveitis anatomical subtype or syndrome. Previous studies suggest that 
the prognosis may vary across uveitis subtype and this should be considered when 
counselling patients pre-operatively [12,14]. The inclusion strategy means the eyes 
included were predominantly those where the surgeon selected the co-pathology 
‘uveitis’ at the time of operation. With regard to the use of corticosteroids, 
immunosuppressants and other treatments, the EMR could only capture a limited 
range of data, which was not sufficient to undertake meaningful subgroup analysis or 
stratification.  
 
Finally, we acknowledge that due to the ‘real-world’ setting of our study the follow-up 
visits were not fixed. We dealt with this by grouping follow-up visits into pre-specified 
intervals reflecting clinically relevant follow-up periods. Whilst not all patients had 
visits during all three time-frames reported, the scale of the study means that at any 
single time point, more than 400 uveitic eyes and 28 000 non-uveitic eyes were 
assessed. Indeed in the 4-12 week time-point, 595 uveitic eyes and 50 611 non-
uveitic eyes were assessed, an unparalleled resource from a single study. 
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 No Uveitis Uveitis P value 
Mean SD n Mean SD n 
Age (years) 74.36 10.77 95568 66.43 15.35 1173 <0.0001 
Pre-op VA 
(logMAR) 0.65 0.55 95471 0.87 0.70 1172 <0.0001 
Axial length 
(mm) 23.49 1.40 95507 23.23 1.50 1173 <0.0001 
Pre-op IOP 
(mmHg) 16.41 3.67 67584 16.03 5.30 780 0.0043 
 
Table 1. Pre-operative continuous data characteristics of the Uveitis and reference 
groups. Pre-op VA and IOP values are within 3 months of surgery unless stated otherwise. P 
values are shown for multiple t tests using the Holm-Sidak method for multiple comparisons 
using an α of 5.00. SD = Standard deviation, VA = Visual acuity, pre-op = pre-operatively, 
IOP = Intraocular pressure. logMAR = logarithm of the minimum angle of resolution, mm= 
millimetres, mmHg = millimetres of mercury. 
 
 
 
Table 2. Pre-operative nominal data characteristics of the Uveitis and reference 
groups. DR = Diabetic retinopathy, ETDRS = Early treatment of diabetic retinopathy study, 
PRP = Panretinal photocoagulation, NSAID = Non-steroidal anti-inflammatory drug, CNS = 
central nervous system, PGA = Prostaglandin analogue, Pre-op = pre-operatively. P-values 
from Chi-square test for independence. 
 
 
Nominal characteristic No Uveitis Uveitis 
No. of 
eyes 
Frequency 
(%) 
No. of 
eyes 
Frequency 
(%) 
P-value 
Baseline 
Total number of eyes 95573 - 1173 - - 
Laterality 
Left eye 46886 49.1 601 51.2 0.1380 
Right eye 48687 50.9 572 48.8 
Gender 
Male 40252 42.1 471 40.2 0.1758 
Female 55320 57.9 702 59.8 
Intravitreal Steroid use  
Any time Pre-op  180 0.18 14 1.19 <0.0001 
Within 3 months Pre-op 19 0.01 5 0.43 <0.0001 
Topical NSAID use  
Pre-op 18 0.02 2 0.17 0.0102 
Other co-pathology excluding uveitis  
Single 32012 33.49 432 36.82 0.0177 
Multiple 268 0.28 147 12.53 <0.0001 
Co-pathology subgroups  
Epiretinal membrane 1300 1.36 11 0.94 0.2146 
Amblyopia 855 0.89 6 0.51 0.1650 
Corneal pathology 2502 2.62 21 1.79 0.0771 
Previous retinal detachment 
surgery 955 1.00 6 0.51 0.0941 
Previous trabeculectomy 44 0.05 3 0.26 0.0012 
Glaucoma 6628 6.94 148 12.62 <0.0001 
White cataract 2295 2.40 38 3.24 0.0629 
High Myopia 2740 2.87 10 0.85 <0.0001 
Optic Nerve/CNS disease 189 0.20 0 0 0.1274 
Pseudoexfoliation/ 
phacodonesis 606 0.63 2 0.17 0.0458 
Pre-op topical PGA use  7583 7.93 160 13.64 <0.0001 
Previous retinal vein occlusion 838 0.88 13 1.11 0.3988 
Age-related Macular 
Degeneration 5477 5.73 14 1.19 <0.0001 
Diabetes Mellitus  
Any Diabetes 23286 24.4 242 20.6 0.0031 
Type I Diabetes 1799 1.9 25 2.1 0.5332 
Type II Diabetes 21104 22.1 213 18.2 0.0013 
Diabetic Retinopathy (eyes with ETDRS data) 
Eyes with ETDRS data 
available 9142 - 88 - - 
No retinopathy 4987 54.6 47 53.4 0.8306 
Maculopathy 662 7.2 4 4.5 0.3307 
Non-proliferative DR 3107 34.0 31 35.2 0.8067 
Proliferative DR 408 4.5 4 4.5 0.9702 
Previous PRP, stable  
Retinopathy 640 7.0 6 6.8 0.9468 
 
 
 
Table 3. Intraoperative and post-operative nominal data characteristics of the Uveitis 
and reference groups. PC = Posterior capsule, IOL = Intraocular lens, Phaco = 
Phacoemulsification cataract surgery, NSAID = Non-steroidal anti-inflammatory drug, P-
values from Chi-square test for independence. 
 
 
 
 
 
 
 
  
Nominal characteristic No Uveitis Uveitis 
No. of 
eyes 
Frequency  
(%) 
No. of 
eyes 
Frequency 
(%) 
P-value 
Baseline 
Total number of eyes 95573 - 1173 - - 
Pupil size 
Small 3113 3.26 287 24.47 <0.0001 
 Medium 13669 14.30 186 15.86 
Large 78791 82.44 700 59.68 
Seniority of operating surgeon 
Consultant 52669 55.11 856 72.98 <0.0001 
Non-consultant 42904 44.89 317 27.02 
Type of Surgery  
Phaco + IOL alone 89403 93.54 848 72.3 <0.0001 
Phaco + Iris procedure 
(iris hooks, pupil ring, sphincterotomy, 
iris stretch or synaechiolysis) 
560 0.59 91 7.76 <0.0001 
Phaco + Glaucoma procedure 
(trabeculectomy, cyclodiode, needling, 
MIGS or gonio surgery) 
881 0.92 42 3.58 <0.0001 
Phaco + injection of drug 
(Intravitreal or sub-tenon injection) 78 0.08 29 2.47 <0.0001 
Phaco + Capsular tension ring 153 0.16 32 2.72 <0.0001 
Phaco + Pars Plana 
Vitrectomy 138 0.14 8 0.68 <0.0001 
Other (including multiple surgical 
procedures) 4276 4.47 117 9.97 <0.0001 
Intraoperative complications  
Any complication 3719 3.89 69 5.88 0.0005 
PC rupture – with or without 
vitreous loss (all surgeons) 1787 1.87 28 2.39 0.1944 
PC rupture – with or without 
vitreous loss (consultant only) 804 0.84 18 1.53 0.0101 
Intravitreal Steroid use 
Any time Post-op  271 0.28 20 1.70 <0.0001 
Within 3 months Post-op 48 0.05 6 0.51 <0.0001 
Topical NSAID use 
Post-op 2975 3.11 118 10.06 <0.0001 
Pseudophakic macular oedema (non-diabetic eyes) 
Total non-diabetic eyes 72300 - 931 - 
<0.0001 
 
Non-diabetic eyes with 
pseudophakic macular 
oedema 
999 1.38 31 3.33 
 No Uveitis Uveitis P value 
Mean SD n Mean SD n 
Post-op VA (logMAR) 
4 week 0.32 0.41 42174 0.52 0.57 531 <0.0001 
4-12 week 0.22 0.36 50611 0.36 0.48 595 <0.0001 
12-24 week 0.27 0.38 28305 0.41 0.54 421 <0.0001 
Improvement 
in VA from 
baseline to 
12-24 week 
0.34 0.52 25789 0.4 0.61 398 0.0227 
IOP (mmHg) 
Post-op 15.23 3.97 57514 15.54 5.91 688 0.0432 
 
Table 4. Post-operative continuous data characteristics of the Uveitis and reference 
groups. Post-op VA values are the latest recorded value within the time period. Post-op IOP 
is the first recorded in the EMR within 3 months of surgery. P values are shown for multiple t 
tests using the Holm-Sidak method for multiple comparisons using an α of 5.00. SD = 
Standard deviation, VA = Visual acuity, mmHg = millimetres of mercury, IOP = Intraocular 
pressure, logMAR = logarithm of the minimum angle of resolution. 
 
  
 
 
Supplementary Figure 1. No correlations were identified between contributing clinical 
sites in terms of surgeon or operation numbers. Mean visual acuity improvement for five 
sites where separate data was available for all cataract surgery was correlated with A) the 
total number of cataract operations recorded and B) total number of surgeons at each site. 
No statistically significant correlations were observed. Pearson correlation used. 	
 
 
 
